Case-Based Roundtable Meetings Spotlight: July 1, 2022

Khan Reviews Later-Line Therapy Options for DLBCL With Subgroup Considerations

July 10, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

Roundtable Discussion: Barata Explores Second- and Third-Line Options for Recurrent RCC

July 08, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed the case of a patient with clear cell renal cell carcinoma who progressed following frontline treatment with axitinib/pembrolizumab.

Bishop Reviews Risk Assessment and Treatment for GVHD

July 06, 2022

Clinical Articles

Michael R. Bishop, MD, discussed a patient with graft-versus-host disease who first underwent a myeloablative conditioning regimen and peripheral blood stem-cell matched hematopoietic cell transplant as treatment.

Burger Details the Data to Help Choose Treatment in Chronic Lymphocytic Leukemia

July 03, 2022

Clinical Articles

During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.